Slideshow

Interesting T2DM: Pharmacotherapy & Obesity Outcomes

Author(s):

Our April list includes CV events with DPP-4 or SGLT2 inhibitors vs. insulin, and impact of obesity on nonalcoholic fatty liver disease and thyroid function.

We present a selection of interesting endocrinology articles for the month of April in the following slides. See the slide legends for links to the article summaries.

Related Videos
Diabetes Dialogue: Diabetes Tech Updates from November 2024 | Image Credit: HCPLive
Viet Le, DMSc, PA-C | Credit: APAC
Diabetes Dialogue: Tirzepatide’s Long-Term Obesity Data | Image Credit: HCPLive
Diabetes Dialogue: Latest Updates on Semaglutide Shortage, Data | Image Credit: HCPLive
HCPLive CKD and CVD NewsNetwork Thumbnail
HCPLive CKD and CVD NewsNetwork Thumbnail
HCPLive CKD and CVD NewsNetwork Thumbnail
HCPLive CKD and CVD NewsNetwork Thumbnail
HCPLive CKD and CVD NewsNetwork Thumbnail
Richard Pratley, MD | Credit: Advent Health Diabetes Institute
© 2024 MJH Life Sciences

All rights reserved.